Hannah Yong Wen, MD, PhD
Director, Breast Pathology Fellowship
Breast Pathology; Oncologic Pathology
Request an Opinion
We can assess your case without an appointment. Click below or call us to get started.
Dr. Wen accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, Beijing Medical University (China); PhD, University of Texas MD Anderson Cancer Center
NYU Medical Center
Memorial Sloan Kettering Cancer Center
Anatomic Pathology; Clinical Pathology
As a board-certified pathologist with a specialization in breast pathology, I perform microscopic examination of breast biopsies and surgical specimens and make diagnoses that help guide treatment decisions for our patients. I am proud to be part of the multidisciplinary team providing breast cancer patients with comprehensive and coordinated care.
I am interested in the molecular and genetic mechanisms of breast cancer development, progression, and response to treatments. My current research is focused on triple negative breast carcinoma — a subgroup of breast cancer that does not express estrogen and progesterone receptors, or the human epidermal growth factor receptor 2 (HER2). I also work closely with my colleagues from surgery, medical oncology, and radiation oncology on a variety of clinical studies in breast cancer.
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Wen Y and Liu B. The role of platelet activating factor in reproduction. Progress of Anatomical Sciences (China). 1996; 2: 204-211
Wen Y and Liu B. Transforming growth factor a and its receptor in reproduction process. Medical Sciences (China). 1997; 16: 27-30
Wen Y and Liu B. The expression of transforming growth factor a in the mouse embryos and preimplantation uterus. J. Beijing Medical. University. 1997; 29:12-14
Yan DH, Wen Y, Spohn B, Choubey D, Gutterman J U, and Hung MC Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202. Oncogene 1999; 18: 807-811
Wen Y, Yan DH, Spohn B, Deng J, Lin SY, and Hung MC. Tumor suppression and sensitization to tumor necrosis factor a-induced apoptosis by an interferon inducible protein, p202, in breast cancer cells. Cancer Res. 2000; 60:42-46
Lin SY, Xia W, Wang J, Kwong KY, Sphon B, Wen Y, Pestell R, and Hung MC. b-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc.Natl. Acad. Sci. U.S.A. 2000; 97: 4262-4266
Wen Y, Hu M, Makino K, Spohn, B, Bartholomeusz G, Yan DH, and Hung MC. HER-2/neu promotes androgen-independent progression of prostate cancer cells through the Akt pathway. Cancer Res. 2000; 60:6841-6845
Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, and Hung MC. Nuclear localization of EGF receptor and its potential new role as a transcriptional factor. Nature Cell Biology 2001; 3:802-808
Wen Y, Yan DH, Spohn B, Xie K, Wang B, Shao R, Ding Y, and Hung MC. p202, an interferon-inducible protein, mediates anti-tumor activity in human pancreatic cancer cells. Cancer Res. 2001; 61:7142-7147
Zou Y, Peng H, Zhou B, Wen Y, Wang SC, Tsai EM, and Hung MC. Systemic tumor suppression by the proapoptotic gene bik. Cancer Res. 2002; 62: 8-12
Lee WP, Wen Y, Varnum B, and Hung MC. Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis. Oncogene 2002; 21:329-336
Ding Y, Wen Y, Spohn B, Wang L, Xia W, Kwong KY, Shao R, Li Z, Hortobagyi G, Hung MC, and Yan DH. Proapoptotic and Antitumor Activities of Adenovirus-mediated p202 Gene Transfer. Clin Cancer Res 2002; 8:3292-3297
Deng J, Miller SA, Wang HY, Xia W, Wen Y, Zhou BP, Li Y, Lin SY, and Hung MC. Beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell 2002; 2:323-334
Yan DH, Abramian A, Li Z, Ding Y, Wen Y, Liu TJ, and Hunt K. p202, an Interferon-Inducible Protein, Inhibits E2F1-Mediated Apoptosis in Prostate Cancer Cells. Biochemical and biophysical research communications (BBRC) 2003; 303: 219-222
Li Y, Wen Y, Zhou BP, Kuo HP, Ding Q, and Hung MC. Enhancement of Bik Anti-Tumor Effect bu Bik Mutant. Cancer Res. 2003; 63:7630-7633
Wen Y, Giri D, Spohn B, Zinner RG, Xia W, Thompson TC, Matusik RJ, Zou Y, Yan DH, and Hung MC. Prostate Specific Anti-tumor Activity by Probasin Promoter-Directed p202 Expression. Mol. Carcinogenesis 2003; 37:130-137
Deng J, Xia W, Miller SA, Wen Y, Wang HY, and Hung MC. Crossregulation of NF-kappa B by the APC/GSK beta/beta-catenin pathway. Mol. Carcinog. 2004; 39:139-146
Yan DH*, Wen Y*, Su LK, Xia W, Wang SC, Zhang S, Gan L, Hortobagyi GN, and Hung MC. A delayed chemically-induced tumorigenesis in Brca2 mutant mice. Oncogene 2004; 23:1896-1901 (equal contribution)
Shao R, Lee DF, Wen Y, Ding Y, Xia W, Ping B, Yagita H, Spohn B, and Hung MC. E1A Sensitizes Cancer Cells to TRAIL-Induced Apoptosis through Enhancement of Caspase Activation. Molecular Cancer Res. 2005; 3:219-226
Cha TL, Lin Q, Chen CT, Wen Y, and Hung MC. Emodin Induces Androgen Receptor Degradation and Suppresses Prostate Cancer Cell Growth. Cancer Res. 2005; 65: 2287-2295
Wen YH, Koeppen H, Garcia R, Chiriboga L, Tarlow B, Peters B, Eigenbrot C, Yee H, Steiner G, and Greco MA. Epidermal Growth Factor in Osteosarcoma: Expression and Mutational Analysis. Human Pathol 2007; 38:1184-1191
Wen YH, Giashuddin S, Shapiro RL, Velazquez FE, and Melamed J. Unusual Occurrence of a Melanoma with Intermixed Epithelial Component: A True melanocarcinoma? Case Report and Review of Epithelial Differentiation by Light Microscopy and Immunohistochemistry. Am J Dermatopathol 2007; 29:395-399
Wen YH, Shi X, Chiriboga L, Matsahashi S., Yee H, and Afonja O. Alterations in the expression of PDCD4 in ductal carcinoma of the breast. Oncology report 2007; 18:1387-1393
Rapkiewicz A, Wen YH, Sen F, Das K. Cytomorphologic examination of anaplastic large cell lymphoma by fine-needle aspiration cytology. Cancer. 2007; 111:499-507
Morris LG, Wen YH, Nonaka D, Kutler DI, Huan Y, and Wang B. PNL2 melanocytic marker in immunohistochemical evaluation of primary mucosal melanoma of the head and neck. Head Neck. 2008;30:771-775
Wen YH, Yee H, Goswami S, Shukla P. Fascin Expression in Serous Tumors of Ovary Correlates with Aggressiveness of Malignancy. Int J Gynecol Cancer 2009; 28:187-192
Flavin R, Smyth P, Barrett C, Russell S, Wen YH, Wei J, Laios A, O’Toole S, Ring M, Denning K, Li J, Aherne S, Sammarae D, Aziz NA, Alhadi A, Finn SP, Loda M, B S, Sheils O, O’Leary JJ. mir-29b expression is associated with disease-free survival in ovarian serous carcinoma patients. Int J Gynecol Cancer 2009; 19: 641-647
Peng L, Wen Y, Han Y, Wei A, Shi G, Mizuguchi M, Lee P, Hernando E, Mittal K, and Wei JJ. Expression of Insulin-Like Growth Factors (IGFs) and IGF Signaling: Molecular Complexity in Uterine Leiomyomas. Fertil Steril 2009; 91:2664-2675
Chandra P, Wen YH, Tuli S, Raphael BG, Amorosi EL, Medeiros LJ, and Ibrahim S. Post-Chemotherapy Histiocyte-rich Pseudotumor Involving the Spleen. Am J Clin Pathol. 2009; 132: 342-348
Wang S, Yee H, Wen YH, Wang BY. Papillomas of the External Ear Canal: Report of Ten Cases in Chinese Patients with HPV In Situ Hybridization. Head Neck Pathol. 2009; 3:207-211
Wolf JH, Wen YH, Axelrod D, Roses D, Guth A, Shapiro R, Cohen J, Singh B. Higher Volume at Time of Breast Conserving Surgery Reduces Re-excision in DCIS. Int J Surg Oncol. 2011; 2011:785803. Epub 2011 Mar 9
D’Arcy C, Wen YH, Stadler ZK, Brogi E, Shia J. Synchronous breast cancers with different morphologic and molecular phenotypes occurring in Lynch syndrome: what does the heterogeneity imply? Am J Surg Pathol. 2011; 35:1743-1748
Ho AY, Gupta G, King TA, Perez CA, Patil SM, Rogers KH, Wen YH, Brogi E, Morrow M, Hudis CA, Traina T, McCormick B, Powell SN, Robson ME. Favorable Prognosis in Patients with T1a/T1bN0 Triple Negative Breast Cancers Treated With Multimodality Therapy. Cancer 2012; 118: 4944-4952
Wen YH, Ho A, Patil S, Akram A, Catalano J, Norton L, Benezra R, Brogi E. Id4 Protein is Highly Expressed in Triple Negative Breast Carcinomas: Possible Implications for BRCA1 Downregulation. Breast Cancer Res Treat. 2012; 135: 93-102
Wen YH, Brogi E, Zeng Z, Akram M, Catalano J, Paty P, Norton L, Shia J. DNA Mismatch Repair Deficiency in Breast Carcinoma: a Pilot Study of Triple Negative and non-Triple Negative Tumors. Am J Surg Pathol. 2012; 36:1700-1708
Zhang X, Jin X, Malladi S, Zou Y, Wen YH, Brogi E, Smid M, Foekens J, and Massagué J. Selection of Bone Metastasis Seeds by Mesenchymal Signals in the Primary Tumor Stroma. Cell 2013; 154:1060-1073
Wen YH, Brogi E, Hasanovic A, Ladanyi M, Soslow R, Chitale D, Shia J, Moreira AL. Immunohistochemical staining with EGFR mutation specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma. Modern Pathol. 2013; 26:1197-1203
Weigelt B, Ng CKY, Wen YH, Reis-Filho JS. Combining two antibodies to define E-cadherin loss of expression in non-lobular carcinomas: when less is more. Histopathology 2013; 63:439-440
Perez CA, Zumsteg Z, Gupta G, Morrow M, Arnold B, Patil SM, Traina TA, Robson ME, Wen YH, McCormick, B, Powell SN, Ho AY. Black race as a prognostic factor in triple negative breast cancer patients treated with breast conserving therapy: A large, single-institution retrospective analysis. Breast Cancer Res Treat. 2013; 139: 497-506
Sung JS, Jochelson MS, Brennan S, Joo S, Wen YH, Moskowitz C, Zheng J, Dershaw DD, Morris EA. MR Imaging Features of Triple Negative Breast Cancers. Breast J. 2013; 19:643-649
Gupta GP, Vanness K, Barlas A, Manova-Todorova KO, Wen YH, and Petrini JHJ. The Mre11 Complex Suppresses Oncogene-driven Breast Tumorigenesis and Metastasis. Mol Cell 2013; 52:353-365
Schrader K, Stratton K, Murali R, Laitman Y, Cavallone L, Offit L, Wen YH, Thomas T, Shah S, Rau-Murthy R, Manschreck C, Salo-Mullen E, Otegbeye E, Corines M, Norton L, Hudis C, Klein R, Kauff N, Robson M, Stadler Z, Haber D, Lipkin S, Friedman E, Foulkes WD, Altshuler D, Vijai J, Offit K. Genome Sequencing of Multiple Primary Tumors Reveals Novel PALB2 Variant. J Clin Oncol.2016; 34: e61-67 Epub 2014 June 30
Weinreb I, Piscuoglio S, Martelotto LG, Waggott D, Ng CKY, Perez-Ordonez B, Harding NJ, Alfaro J, Chu KC, Viale A, Fusco N, da Cruz Paula A, Marchio C, Sakr RA, Lim R, Thompson LDR, Chiosea SI, Seethala RR, Skalova A, Stelow EB, Fonseca I, Assaad A, How C, Wang J, de Borja R, Chan-Seng-Yue M, Howlett CJ, Nichols AC, Wen YH, Katabi N, Buchner N, Mullen L, Kislinger T, Wouters BG, Liu F , Norton L, McPherson JD , Rubin BP, Clarke BA, Weigelt B, Boutros PC, Reis-Filho JS. Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nature Genetics. 2014; 46:1166-1169
Tozbikian G, Brogi E, Kadota K, Catalano J, Akram M, Patil S, Ho AY, Reis-Filho JS, Weigelt B, Norton L, Adusumilli PS, Wen, HY*. Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-like Phenotype, Distant Metastases and Decreased Survival. PLoS ONE 2014; 9: e114900. (*corresponding author)
Piscuoglio S, Hodi Z, Katabi N, Guerini-Rocco E, De Souza Macedo G, Ng CKY, de Mattos Arruda L, Wen HY, Rakha EA, Ellis IO, Rubin BP, Weigelt B and Reis-Filho JR. Are acinic cell carcinomas of the breast and salivary glands distinct diseases? Histopathology 2015; 67:529-537
Kleppe M, Comen E, Wen, HY, Bastian L, Blum B, Rapaport FT, Keller M, Granot Z, Socci N, Viale A, You D, Benezra R, Weigelt B, Reis-Filho JS, Brogi E, Berger MF, Levine RL, Norton L. Leukocytes Infiltrating Primary Breast Cancers Harbor Oncogenic Mutations. NPG Breast Cancer 2015; 1: article number 15005
Martelotto LG, De Filippo MR, Ng CK, Natrajan R, Fuhrmann L, Cyrta J, Piscuoglio S, Wen HC, Lim RS, Shen R, Schultheis AM, Wen YH, Edelweiss M, Mariani O, Stenman G, Chan TA, Colombo PE, Norton L, Vincent-Salomon A, Reis-Filho JS, Weigelt B. Genomic Landscape of Adenoid Cystic Carcinoma of the Breast. J Pathol 2015; 237:179-189
Guerini-Rocco E, Piscuoglio S, Ng CKY, De Filippo MR, Geyer FC, Eberle CA Akram M, Fusco N, Ichihara S, Vincent-Salomon A, Ellis IO, Wen HY, Weigelt B, Schnitt SJ, and Reis-Filho JS. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harboring TP53 somatic mutations. J Pathol 2016; 238: 677-688
Ebbesen SH, Scaltriti M, Bialucha CU, Morse N, Kastenhuber ER, Wen HY, Dow LE, Baselga J, Lowe SW. PTEN loss promotes MAPK pathway dependency in HER2/neu breast carcinomas. Proc Natl Acad Sci U S A. 2016; 113: 3030-3035
Weisman P, Ng CKY, Brogi E, Eisenberg R, Won HH, Piscuoglio S, De Filippo MR, Ioris R, Akram M, Norton L, Weigelt B, Berger MF, Reis-Filho JS, and Wen HY*. Genetic Alterations of Triple Negative Breast Cancer By Targeted Next Generation Sequencing And Correlation With Tumor Morphology. Mod Pathol 2016; 29:476-488. (*corresponding author)
Qian XL, Wen HY, Yang YL, Gu F, Guo XJ, Liu FF, Zhang L, Zhang XM, Fu L. Assessment Of Dual-Probe Her-2 Fluorescent In Situ Hybridization In Breast Cancer By 2013 ASCO/CAP Guidelines Produces More Equivocal Results Than That By 2007 ASCO/CAP Guidelines. Breast Cancer Res Treat July 25, 2016; 159: 31-39. Epub ahead of print 2016 July 25
Tozbikian G, Brogi E, Vallejo CE, Giri D, Murray M, Catalano J, Olcese C, Patil S, Van Zee KJ, Wen HY*. Atypical Ductal Hyperplasia Bordering on Ductal Carcinoma In Situ: Interobserver Variability and Outcomes in 105 Cases. Int J Surg Pathol 2016, July 31. Epub ahead of print (*corresponding author)
Wen HY, Krystel-Whittemore M, Pareja F, Bowser ZL, Morrow M, Dickler M, Hudis C and Brogi E. Breast Carcinoma with Oncotype DX Recurrence Score Lower Than 18: Rate of Distant Metastases in a Large Series with Clinical Follow-up. Cancer. 2016, Aug 15. Epub ahead of print
McArthur HL, Diab A, Page D, Yuan J, Solomon SB, Sacchini V, Comstock C, Durack JC, Sung J, Maybody M, Ginsberg A, Wong P, Barlas A, Dong Z, Blum B, Patil S, Neville DA, Comen EA, Morris EA, Kotin A, Brogi E, Wen HY, Morrow M, Lacouture M, Sharma P, Allison JP, Hudis CA, Wolchok JD, and Norton L. A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. Clin Cancer Res 2016, Aug 26. Epub ahead of print
Page DB, Yuan J, Redmond D, Wen HY, Durack JC, Emerson R, Solomon S, Dong Z, Wong P, Comstock C, Diab A, Sung J, Maybody M, Morris EA, Brogi E, Morrow M, Sacchini V, Elemento O, Robins H, Patil S, Allison JP, Wolchok JD, Hudis C, Norton L, and McArthur H. T-cell Receptor DNA Deep Sequencing as a Biomarker of Clonality Expanded TILs in Breast Cancer After Immunotherapy. Cancer Immunol Res 2016; 4: 835-844. Epub ahead of print 2016 Sep 1
Geyer FC, Berman SH, Marchiò C, Burke K, Guerini-Rocco E, Piscuoglio S, Ng CKY, Pareja F, Wen HY, Hodi Z, Rakha EA, Ellis IO, Schnitt S, Norton L, Weigelt B and Reis-Filho JS. Genetic Analysis of Microglandular Adenosis and Acinic Cell Carcinomas of the Breast Provides Evidence for the Existence of a Low-grade Triple-Negative Breast Neoplasia Family. Modern Pathol 2016, Oct 7. Epub ahead of print
Zuo Z, Chandra P, Wen YH, Koeppen H. Molecular Diagnosis of Acute Myeloid Leukemia. Diagnostic Histopathology 2009; 15: 531-539
Wen YH, Weigelt B, and Reis-Filho JS. Microglandular Adenosis: a Non-Obligate Precursor of Triple-Negative Breast Cancer? Histol Histopathol. 2013, 28:1099-1108
Ross DS, Wen YH, Brogi E. Ductal Carcinoma in situ: Morphology-Based Knowledge and Molecular Advances. Adv Anat Pathol. 2013. 20:205-216
Weisman P and Wen HY. Commentary on “Impact of Analysis of Frozen-section Margin on Reoperation Rates In Women Undergoing Lumpectomy For Breast Cancer: Evaluation Of The National Surgical Quality Improvement Program Data”. Breast Disease: A Yearly Book Quarterly. 2015; 26:159
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Hannah Yong Wen discloses the following relationships and financial interests:
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.